MedDataX Logo

24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination

NCT ID: NCT00331240

Last Updated: 2014-05-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the short-term (8 week) mean 24-hour intraocular pressure control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given once in the morning with placebo once in the evening in patients with open-angle glaucoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy

NCT01779284

Glaucoma
COMPLETED PHASE4

24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG

NCT00757835

Glaucoma
COMPLETED PHASE4

24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost

NCT00444184

Glaucoma
COMPLETED PHASE4

24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients

NCT00330577

Primary Open Angle Glaucoma Ocular Hypertension
COMPLETED PHASE4

24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol

NCT00981786

Glaucoma
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma Exfoliation Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

travoprost/timolol fixed combination

Intervention Type DRUG

placebo (artificial tears)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* POAG
* Exfoliation syndrome

Exclusion Criteria

* Advanced glaucoma
Minimum Eligible Age

29 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aristotle University Of Thessaloniki

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AGP Konstas

Professor in Ophthalmology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AGP Konstas, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital

Thessaloniki, , Greece

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A1457

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00672997 COMPLETED PHASE3
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
NCT03868124 COMPLETED PHASE3
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00333125 COMPLETED PHASE3
24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
NCT00486486 COMPLETED PHASE4
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure
NCT02003391 COMPLETED PHASE4
Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing
NCT03612817 COMPLETED PHASE4
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
NCT00759239 COMPLETED PHASE4
24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
NCT00397241 COMPLETED PHASE4
Safety and Efficacy of Travoprost/Timolol BAC-free
NCT00760539 COMPLETED PHASE3
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
NCT00372827 COMPLETED PHASE4
24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
NCT00972257 COMPLETED PHASE4
Ocular Surface Disease and IOP Monitoring With Travoprost Without Conservatives
NCT05319470 COMPLETED
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389 COMPLETED PHASE3
Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension
NCT02312544 COMPLETED PHASE2
Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00872651 COMPLETED PHASE3
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
NCT00763061 COMPLETED PHASE4
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy
NCT01514721 TERMINATED PHASE4
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
NCT03519386 COMPLETED PHASE3
Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma
NCT01845038 COMPLETED PHASE1
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
NCT01336569 COMPLETED PHASE4
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
NCT00471380 COMPLETED PHASE4
Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension
NCT00348023 COMPLETED PHASE4
24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
NCT01448837 COMPLETED PHASE4
Safety and Efficacy of Changing to DuoTrav From Prior Therapy
NCT01230736 COMPLETED PHASE4
IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy
NCT00382226 COMPLETED PHASE4